Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Zheng Xiong

Showing results (1-10 of 260) with videos related to

Pageof 26
Sort By:
Drug, Healthcare and Patient Safety|February 1, 2011
Preclinical Pharmacology, Efficacy and Safety of Varenicline in Smoking Cessation and Clinical Utility in High Risk PatientsZheng-Xiong Xi
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|July 5, 2025
Novel potential pharmacological approaches in treating eating disorders comorbid with substance use disordersZheng-Xiong Xi, Ewa Galaj
Acta Pharmacologica Sinica|December 7, 2021
Mitochondrial Clk1-iron-DAT regulation pathway: a possible new therapeutic target for methamphetamine use disorderBriana Hempel, Zheng-Xiong Xi
Pharmacology, Biochemistry, and Behavior|November 23, 2020
Progress in opioid reward research: From a canonical two-neuron hypothesis to two neural circuitsEwa Galaj, Zheng-Xiong Xi
International Journal of Molecular Sciences|December 30, 2020
Possible Receptor Mechanisms Underlying Cannabidiol Effects on Addictive-like Behaviors in Experimental AnimalsEwa Galaj, Zheng-Xiong Xi
Advances in Pharmacology (San Diego, Calif.)|March 28, 2022
Receptor mechanisms underlying the CNS effects of cannabinoids: CB<sub>1</sub> receptor and beyondBriana Hempel, Zheng-Xiong Xi
CNS Drugs|September 25, 2019
Potential of Cannabinoid Receptor Ligands as Treatment for Substance Use DisordersEwa Galaj, Zheng-Xiong Xi
Methods in Molecular Medicine|April 22, 2003
Opiate self-administrationZheng-Xiong Xi, Elliot A Stein
Current Drug Abuse Reviews|May 12, 2009
Hypothesis-driven medication discovery for the treatment of psychostimulant addictionZheng-Xiong Xi, Eliot L Gardner
Expert Opinion on Drug Discovery|March 29, 2018
Discovery and development of varenicline for smoking cessationChloe J Jordan, Zheng-Xiong Xi
Pageof 26

Showing results (1-10 of 260) with videos related to

Sort By:
Pageof 26
Drug, Healthcare and Patient Safety|February 1, 2011
Preclinical Pharmacology, Efficacy and Safety of Varenicline in Smoking Cessation and Clinical Utility in High Risk PatientsZheng-Xiong Xi
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|July 5, 2025
Novel potential pharmacological approaches in treating eating disorders comorbid with substance use disordersZheng-Xiong Xi, Ewa Galaj
Acta Pharmacologica Sinica|December 7, 2021
Mitochondrial Clk1-iron-DAT regulation pathway: a possible new therapeutic target for methamphetamine use disorderBriana Hempel, Zheng-Xiong Xi
Pharmacology, Biochemistry, and Behavior|November 23, 2020
Progress in opioid reward research: From a canonical two-neuron hypothesis to two neural circuitsEwa Galaj, Zheng-Xiong Xi
International Journal of Molecular Sciences|December 30, 2020
Possible Receptor Mechanisms Underlying Cannabidiol Effects on Addictive-like Behaviors in Experimental AnimalsEwa Galaj, Zheng-Xiong Xi
Advances in Pharmacology (San Diego, Calif.)|March 28, 2022
Receptor mechanisms underlying the CNS effects of cannabinoids: CB<sub>1</sub> receptor and beyondBriana Hempel, Zheng-Xiong Xi
CNS Drugs|September 25, 2019
Potential of Cannabinoid Receptor Ligands as Treatment for Substance Use DisordersEwa Galaj, Zheng-Xiong Xi
Methods in Molecular Medicine|April 22, 2003
Opiate self-administrationZheng-Xiong Xi, Elliot A Stein
Current Drug Abuse Reviews|May 12, 2009
Hypothesis-driven medication discovery for the treatment of psychostimulant addictionZheng-Xiong Xi, Eliot L Gardner
Expert Opinion on Drug Discovery|March 29, 2018
Discovery and development of varenicline for smoking cessationChloe J Jordan, Zheng-Xiong Xi
Pageof 26